Sydney - Thursday - August 31: (RWE Aust Business News) - Dia-B
Tech Ltd (ASX:DIA) has moved a step closer to human clinical trials of
its anti-diabetes compound ISF402 after the completion of trials on
animals.
The 28-day repeat dose study on 80 rats found that ISF402 is
safe, said chairman Dr Michael Wooldridge.
"The results of the repeat dose animal toxicology study has
indicated no adverse effects at dose levels well above those planned for
human clinical trials," he said.
"These results show that ISF402 has a good safety profile."
Together with the results of pharmacokinetic studies, which are
currently underway, these studies will clear the path for Dia-B to apply
for human ethics approval to commence Phase 1 human trials in the last
quarter of 2006.
The Phase 1 trial will comprise a single dose trial, with a
likely dosing of between 2 and 30mg per kg of body weight.
This compares to the recently completed rat trials which used
much higher doses of 550mg/kg.
DIA
dia-b tech limited
closer to human trials of diabetes compound
Add to My Watchlist
What is My Watchlist?